Latest: Rainbow Childrens Medicare Ltd Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
RC

Rainbow Childrens Medicare Ltd

Q1 FY27Healthcare Services

Rainbow Childrens Medicare Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹1,249
Market cap₹12.7K Cr
P/E44.3
Updated16 Oct 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned

The short version

Revenue growth target is around 20% annually, aiming to double revenue over approximately 4 years (Page 15). Rainbow Children's Medicare Limited targets ~20% annual revenue growth over the medium term, aiming to double revenues in approximately four years.

From Rainbow Childrens Medicare Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Good growth
  • Revenue growth target is around 20% annually, aiming to double revenue over approximately 4 years (Page 15).
  • Current trajectory expects revenue to cross INR 2,000 crores by the end of the financial year and double in the next four years (Page 10).
  • Volume growth supported by planned addition of 2,500 beds over 5 years (~15% CAGR) (Page 10).
  • New Bengaluru hospitals expected to breakeven within 12-15 months, all within about 18 months (Page 20).
  • Acquisitions in Andhra Pradesh (Nellore, Guntur) expected to stabilize in 6 months and contribute positively to cluster performance by year-end (Page 20).

2 more points from Rainbow Childrens Medicare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Rainbow Childrens Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Invested approximately INR 56 crores towards capital expenditure during the quarter, primarily focused on expanding and strengthening capabilities across existing hospitals and upcoming projects.
  • Planning to add around 2,500 beds over the next five years as part of capacity expansion.
  • Ongoing capital expenditure program funded through strong internal accruals and a robust balance sheet with cash and investments totaling INR 613 crores as of June 30, 2026.
  • Exploring and executing acquisitions and greenfield projects in new markets including Mumbai, Noida, Central India, Bhubaneswar, and Raipur to broaden presence.
  • Focus on building hub-and-spoke networks for operational efficiency and clinical strength.

2 more points from Rainbow Childrens Medicare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rainbow Childrens Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Rainbow Childrens Medicare Ltd said on order book & pipeline — free account, 30 seconds.

Rainbow Childrens Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹548 Cr, net profit ₹84 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital Ltd (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • 3B Blackbio (Q1 FY27)

    Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rainbow Childrens Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rainbow Childrens Medicare Ltd Q1 FY27 results?

Revenue growth target is around 20% annually, aiming to double revenue over approximately 4 years (Page 15). Rainbow Children's Medicare Limited targets ~20% annual revenue growth over the medium term, aiming to double revenues in approximately four years.

What is Rainbow Childrens Medicare Ltd share price analysis?

Rainbow Childrens Medicare Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 44.3 with a market cap of ₹12,682 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rainbow Childrens Medicare Ltd planning capital expenditure?

Invested approximately INR 56 crores towards capital expenditure during the quarter, primarily focused on expanding and strengthening capabilities across existing hospitals and upcoming projects.

Keep Rainbow Childrens Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.